Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.
P/E ratio for Alaunos Therapeutics, Inc. (TCRT)
P/E ratio as of 2023: -0.48
According to Alaunos Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.48. At the end of 2022 the company had a P/E ratio of -3.75.
P/E ratio history for Alaunos Therapeutics, Inc. from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -0.48 |
| 2022 | -3.75 |
| 2021 | -3.04 |
| 2020 | -6.70 |
| 2019 | -4.46 |
| 2018 | -5.05 |
| 2017 | -10.44 |
| 2016 | -4.22 |
| 2015 | -8.68 |
| 2014 | -16.13 |
| 2013 | -6.53 |
| 2012 | -3.40 |
| 2011 | -4.56 |
| 2010 | -6.56 |
| 2009 | -8.94 |
| 2008 | -0.49 |
| 2007 | -2.51 |
| 2006 | -4.20 |
| 2005 | -1.85 |
| 2004 | -60.85 |
| 2003 | -131.11 |
| 2002 | -89.77 |
| 2001 | -49.43 |